September 3rd, 2010
Posted on 08. Feb, 2010 by PublicWire in Medical
2/8 (MSBT.OBB) MedaSorb Technologies’ CytoSorb Hailed As Medicines Holy Grail
MedaSorb Technologies’ (OTCBB: MSBT) flagship product CytoSorb™ — a therapeutic device, may be a Holy Grail which has eluded medicine for decades.
Severe sepsis is a life-threatening condition, which affects over 18 million people each year.
“Unfortunately, most know someone who had developed a severe infection. It could have been something as catastrophic as a ruptured appendix, or something more common as pneumonia, maybe a bad urinary tract infection or even influenza — where the infection got out of hand and sent that person to the intensive care unit on life support, with failing critical organs like the hearts, lungs, and kidneys,” says Dr. Phillip Chan, MD, PhD, the Chief Executive Officer of the company.
“Despite the best medical care here in the United States, one in every three patients die of this disease, and in fact, more people die of severe sepsis in the United States than from either heart attacks or strokes or any single form of cancer. It remains a major unmet medical need.”
While massive resources have been invested in developing and evaluating potential therapies, MedaSorb is conducting human trials in Europe and has already announced preliminary positive proof of concept in humans, using CytoSorb™ to treat severe sepsis patients.
“Our major goal (for 2010) is the successful completion of our trial, which will hopefully lead to CE Mark approval,” Chan said.
